Skip to Content

Rydex Biotechnology C RYCFX

Medalist Rating as of | See Rydex Investment Hub
  • NAV / 1-Day Return 50.84  /  −2.27 %
  • Total Assets 115.9 Mil
  • Adj. Expense Ratio
    2.390%
  • Expense Ratio 2.390%
  • Distribution Fee Level High
  • Share Class Type Level Load
  • Category Health
  • Investment Style Mid Blend
  • Min. Initial Investment 2,500
  • Status Open
  • TTM Yield
  • Turnover 61%

USD | NAV as of Feb 29, 2024 | 1-Day Return as of Feb 29, 2024, 11:20 PM GMT+0

Morningstar’s Analysis RYCFX

Will RYCFX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

The combination of an Average People Pillar rating and a Below Average Process Pillar rating limit Rydex Biotechnology C to a Morningstar Medalist Rating of Negative.

null Morningstar Manager Research

Morningstar Manager Research

Summary

Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the highest quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings RYCFX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 40.0
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

AbbVie Inc

7.77 8.7 Mil
Healthcare

Amgen Inc

5.88 6.6 Mil
Healthcare

Vertex Pharmaceuticals Inc

4.31 4.8 Mil
Healthcare

Regeneron Pharmaceuticals Inc

4.23 4.8 Mil
Healthcare

Gilead Sciences Inc

4.21 4.7 Mil
Healthcare

Moderna Inc

3.00 3.4 Mil
Healthcare

Biogen Inc

2.93 3.3 Mil
Healthcare

Corteva Inc

2.75 3.1 Mil
Basic Materials

AstraZeneca PLC ADR

2.61 2.9 Mil
Healthcare

Illumina Inc

2.33 2.6 Mil
Healthcare